Your browser doesn't support javascript.
loading
Renshen Yangrong decoction for secondary malaise and fatigue: network pharmacology and Mendelian randomization study.
Wang, Fanghan; Zhu, Liping; Cui, Haiyan; Guo, Shanchun; Wu, Jingliang; Li, Aixiang; Wang, Zhiqiang.
Afiliación
  • Wang F; Department of Medical Oncology, The Fourth People's Hospital of Zibo, Zibo, China.
  • Zhu L; Department of Medical Oncology, Shouguang Hospital of Traditional Chinese Medicine, Shouguang, China.
  • Cui H; Department of Pathology, The Fourth People's Hospital of Zibo, Zibo, China.
  • Guo S; RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA, United States.
  • Wu J; Medical School, Weifang University of Science and Technology, Shouguang, China.
  • Li A; Department of Medical Oncology, Shouguang Hospital of Traditional Chinese Medicine, Shouguang, China.
  • Wang Z; Department of Urology, Shouguang Hospital of Traditional Chinese Medicine, Shouguang, China.
Front Nutr ; 11: 1404123, 2024.
Article en En | MEDLINE | ID: mdl-38966421
ABSTRACT

Background:

Renshen Yangrong decoction (RSYRD) has been shown therapeutic effects on secondary malaise and fatigue (SMF). However, to date, its bioactive ingredients and potential targets remain unclear.

Purpose:

The purpose of this study is to assess the potential ingredients and targets of RSYRD on SMF through a comprehensive strategy integrating network pharmacology, Mendelian randomization as well as molecular docking verification.

Methods:

Search for potential active ingredients and corresponding protein targets of RSYRD on TCMSP and BATMAN-TCM for network pharmacology analysis. Mendelian randomization (MR) was performed to find therapeutic targets for SMF. The eQTLGen Consortium (sample sizes 31,684) provided data on cis-expression quantitative trait loci (cis-eQTL, exposure). The summary data on SMF (outcome) from genome-wide association studies (GWAS) were gathered from the MRC-IEU Consortium (sample sizes 463,010). We built a target interaction network between the probable active ingredient targets of RSYRD and the therapeutic targets of SMF. We next used drug prediction and molecular docking to confirm the therapeutic value of the therapeutic targets.

Results:

In RSYRD, network pharmacology investigations revealed 193 possible active compounds and 234 associated protein targets. The genetically predicted amounts of 176 proteins were related to SMF risk in the MR analysis. Thirty-seven overlapping targets for RSYRD in treating SMF, among which six (NOS3, GAA, IMPA1, P4HTM, RB1, and SLC16A1) were prioritized with the most convincing evidence. Finally, the 14 active ingredients of RSYRD were identified as potential drug molecules. The strong affinity between active components and putative protein targets was established by molecular docking.

Conclusion:

This study revealed several active components and possible RSYRD protein targets for the therapy of SMF and provided novel insights into the feasibility of using Mendelian randomization for causal inference between Chinese medical formula and disease.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Front Nutr Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Front Nutr Año: 2024 Tipo del documento: Article